Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    View All Topics
    Advocacy
    • Latest Articles
    • Get Involved
    Stories View All
    View All
    Learn How to Conduct Mock Code Simulations
    Clinical practice
    Learn How to Conduct Mock Code Simulations
    August 18, 2023
    Nurse-Led QI Project Standardizes Transplant and Cellular Therapy Nurse Coordinator Visit Scheduling
    Quality of care
    Nurse Practitioner's QI Project Standardizes Transplant and Cellular Therapy Nurse Coordinator Visit Scheduling
    August 03, 2023
    Nurse-Created Apps Help Pediatric Patients Find Their Voice and Navigate Their Cancer Journey
    Patient Support
    Nurse-Created Apps Help Pediatric Patients Find Their Voice and Navigate Their Cancer Journey
    July 21, 2023
    Certification Was a Critical Step Along My Oncology Nursing Career Journey
    Oncology nursing community
    Certification Was a Critical Step Along My Oncology Nursing Career Journey
    July 14, 2023
    Learn How to Read a Germline Genomic Testing Report
    Genetics & genomics
    Learn How to Read a Germline Genomic Testing Report
    July 07, 2023
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    Drug Reference Sheet

    Oncology Drug Reference Sheet: Capmatinib
    Oncology drug research

    Oncology Drug Reference Sheet: Capmatinib

    In August 2022, the U.S. Food and Drug Administration granted regular approval to capmatinib (Tabrecta®) for adults with metastatic non-small cell lung cancer whose tumors have a variant that leads to mesenchymal-epithelial transition exon 14 skipping. Capmatinib was granted accelerated approval for the same indication in May 2020; the regular approval in August 2022 was based on additional data from 63 patients and follow-up data establishing durability of response and clinical benefit.

    September 26, 2023
    Oncology Drug Reference Sheet: Pirobrutinib
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Pirobrutinib

    In clinical trials, pirobrutinib (Jaypirca™) was effective in restoring BTK inhibition in patients that experienced progression after previously receiving a covalent BTK inhibitor. Pirobrutinib became the first-available noncovalent (reversible) BTK inhibitor in January 2023 when the U.S. Food and Drug Administration granted it accelerated approval.

    August 22, 2023
    Oncology Drug Reference Sheet: Adagrasib
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Adagrasib

    After clinical trials demonstrated a 43% durable objective response rate with a median 8.5-month duration, the U.S. Food and Drug Administration (FDA) granted adagrasib (Krazati™) accelerated approval in December 2022 for adult patients with locally advanced or metastatic non-small cell lung cancer with a KRAS G12C variant, as detected by an FDA-approved test, whose disease has progressed on or after at least one prior systemic therapy.

    July 25, 2023
    Oncology Drug Reference Sheet: Elacestrant
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Elacestrant

    After clinical trial outcomes demonstrated a statistically significant difference in progression-free survival in a subgroup of patients with estrogen receptor-positive, HER2-negative, ESR1-altered disease, the U.S. Food and Drug Administration granted elacestrant’s (Orserdu™) application priority review and fast-track designation, with regular approval in January 2023.   

    July 06, 2023
    Oncology Drug Reference Sheet: Teclistamab-Cqyv
    Oncology drug research

    Oncology Drug Reference Sheet: Teclistamab-Cqyv

    With an estimated duration of response rate of 90.6% at six months and 66.5% at nine months in the agent’s clinical trials, in October 2022, the U.S. Food and Drug Administration granted accelerated approval to teclistamab-cqyv (Tecvayli™) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four previous lines of therapy.  

    June 27, 2023
    Oncology Drug Reference Sheet: Epcoritamab-Bysp
    Oncology drug research

    Oncology Drug Reference Sheet: Epcoritamab-Bysp

    Demonstrating a 61% overall response rate with 38% of patients achieving complete response, epcoritamab-bysp (Epkinly™) became the first CD20-bispecific antibody drug available for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) when the U.S. Food and Drug Administration granted it accelerated approval in May 2023. A phase III trial is currently underway to confirm its clinical benefit compared to the current standard of care for relapsed or refractory DLBCL.

    June 16, 2023
    Oncology Drug Reference Sheet: Mosunetuzumab-Axgb
    Oncology drug research

    Oncology Drug Reference Sheet: Mosunetuzumab-Axgb

    In an open-label, multicenter, multicohort study that included 90 patients with relapsed or refractory follicular lymphoma who had received at least two prior lines of systemic therapy, 60% of patients receiving treatment with mosunetuzumab-axgb achieved a complete response and 80% had an overall response. On December 22, 2022, the U.S. Food and Drug Administration granted mosunetuzumab-axgb accelerated approval based on those findings.

    May 23, 2023
    Oncology Drug Reference Sheet: Nadofaragene Firadenovec-Vncg
    U.S. Food and Drug Administration (FDA)

    Oncology Drug Reference Sheet: Nadofaragene Firadenovec-Vncg

    Under the U.S. Food and Drug Administration’s (FDA’s) fast-track approval process, nadofaragene firadenovec-vncg (Adstiladrin®) became the first gene therapy approved for the treatment of high-risk non-muscle invasive bladder cancer. Approximately 75% of newly diagnosed bladder cancers are classified as non-muscle invasive. Bacillus Calmette Guérin has been used as first-line therapy for more than 20 years, but eventually 30%–50% of patients stop responding, and nadofaragene firadenovec-vncg offers a new treatment option. FDA’s December 2022 approval was based on complete response (CR) and duration of response from Study CS-003, which demonstrated a 46% CR for at least one year.

    April 25, 2023
    Oncology Drug Reference Sheet: Pemigatinib
    U.S. Food and Drug Administration (FDA)

    Oncology Drug Reference Sheet: Pemigatinib

    When the U.S. Food and Drug Administration (FDA) granted pemigatinib (Pemazyre®) a new indication in August 2022, it became the first targeted therapy approved for treatment of patients with relapsed or refractory myeloid or lymphoid neoplasms (MLNs) with fibroblast growth factor receptor (FGFR) 1 rearrangement. In 2021, FDA gave pemigatinib accelerated approval for patients with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement as detected by an FDA-approved test.

    March 28, 2023
    Oncology Drug Reference Sheet: Futibatinib
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Futibatinib

    Patients with rare cancers like intrahepatic cholangiocarcinoma seldom have many additional treatment options if their tumors become resistant to first-line therapy: From August 1, 2021–July 31, 2022, the U.S. Food and Drug Administration approved only five new agents or indications for rare tumors. On September 30, 2022, FDA added one more, giving futibatinib (Lytgobi™) accelerated approval for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 gene fusions or other rearrangements. The approval was based on the drug’s 42% overall response rate and median duration of response of 9.7 months.

    February 28, 2023
    Oncology Drug Reference Sheet: Darolutamide
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Darolutamide

    On August 5, 2022, the U.S. Food and Drug Administration approved darolutamide (Nubeqa®) in combination with docetaxel in adults with metastatic hormone-sensitive prostate cancer. The approval was based on clinical trial findings demonstrating that the agent improved overall survival and significantly delayed time to pain progression compared to placebo.

    January 26, 2023
    Oncology Drug Reference Sheet: Dostarlimab-Gxly
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Dostarlimab-Gxly

    More than 40% of adult patients with mismatch repair deficient recurrent or advanced endometrial cancer had an overall response receiving dostarlimab-gxly (Jemperli), and more than 90% of those lasted six months or longer during the drug’s clinical trials. Those results led the U.S. Food and Drug Administration to grant the agent its original accelerated approval in 2021 for the indication. FDA expanded the accelerated approval later that year to include all recurrent or advanced solid tumors with dMMR demonstrated through an FDA-approved diagnostic test.

    December 20, 2022
    Oncology Drug Reference Sheet: Tebentafusp-Tebn When the U.S. Food and Drug Administration (FDA) approved tebentafusp-tebn (Kimmtrak®) in January 2022 as an orphan drug for unresectable or metastatic uveal melanoma (mUM) in adults, it became the first—and only, at the time of this reference sheet’s publication—drug approved for the indication.
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Tebentafusp-Tebn

    When the U.S. Food and Drug Administration approved tebentafusp-tebn (Kimmtrak®) in January 2022 as an orphan drug for unresectable or metastatic uveal melanoma in adults, it became the first—and only, at the time of this reference sheet’s publication—drug approved for the indication.

    November 22, 2022
    Oncology Drug Reference Sheet: Asparaginase Erwinia Chrysanthemi (Recombinant)–Rywn
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Asparaginase Erwinia Chrysanthemi (Recombinant)–Rywn

    After more than 93% of patients maintained nadir serum asparaginase activity in the therapy’s clinical trials, on June 30, 2021, the U.S. Food and Drug Administration approved asparaginase erwinia chrysanthemi (recombinant)–rywn (RylazeTM) for use as a component of a multiagent chemotherapeutic regimen for treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients who have developed hypersensitivity to E. coli-derived asparaginase.

    October 25, 2022
    Oncology Drug Reference Sheet: Fam-Trastuzumab Deruxtecan-Nxki
    Clinical practice

    Oncology Drug Reference Sheet: Fam-Trastuzumab Deruxtecan-Nxki

    Bringing the first agent to market for the indication, on August 5, 2022, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu®) for patients with unresectable or metastatic HER2-low breast cancer based on results from the DESTINY-Breast04 trial that demonstrated improved progression-free and overall survival. FDA also gave fam-trastuzumab deruxtecan its fourth approval on August 11, 2022, for unresectable or metastatic HER2-activating non-small cell lung cancer (NSCLC).

    October 07, 2022
    Oncology Drug Reference Sheet: Selinexor
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Selinexor

    After clinical trials demonstrated a 25% response rate in patients with multiple myeloma, selinexor (Xpovio®) received initial, accelerated U.S. Food and Drug Administration approval in 2019.

    September 27, 2022
    Oncology Drug Reference Sheet: Nivolumab and Relatlimab-Rmbw
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Nivolumab and Relatlimab-Rmbw

    When OpdualagTM (nivolumab and relatlimab-rmbw), a fixed-dose combination therapy that consists of two distinct monoclonal antibodies, received FDA approval on March 18, 2022, for the treatment of unresectable or metastatic melanoma for adult and pediatric patients 12 years of age or older, it became the first approved combination therapy that includes two distinct immunotherapy agents in a single infusion. Relatlimab-rmbw is also the first approved lymphocyte activation gene-3–blocking antibody.

    August 23, 2022
    Oncology Drug Reference Sheet: Lutetium Lu 177 Vipivotide Tetraxetan
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Lutetium Lu 177 Vipivotide Tetraxetan

    After clinical trial results demonstrated a four-month improvement in overall survival compared to best standard care, in March 2022 the U.S. Food and Drug Administration approved lutetium lu 177 vipivotide tetraxetan (PluvictoTM) to treat prostate-specific membrane antigen–expressing metastatic castration-resistant prostate cancer.

    July 26, 2022
    Oncology Drug Reference Sheet: Loncastuximab Tesirine-Lpyl
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Loncastuximab Tesirine-Lpyl

    Based on LOTIS-2 trial results that reported an overall response rate of nearly 50%, in April 2021 the U.S. Food and Drug Administration granted accelerated approval to loncastuximab tesirine-lpyl (ZynlontaTM) for adults with relapsed or refractory large B-cell lymphoma.

    June 21, 2022
    Oncology Drug Reference Sheet: Belumosudil
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Belumosudil

    Chronic graft-versus-host disease (GVHD) is a severe adverse reaction after allogeneic hematopoietic cell transplantation that decreases quality of life and is a major cause of death. In July 2021, the U.S. Food and Drug Administration approved belumosudil (RezurockTM) as a third-line treatment option for chronic GVHD.

    May 24, 2022
    Oncology Drug Reference Sheet: Avapritinib
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Avapritinib

    First approved by the U.S. Food and Drug Administration in 2020 for treatment of gastrointestinal stromal tumors (GIST), avapritinib’s (AyvakitTM) approval was extended in 2021 for treatment of advanced systemic mastocytosis (AdvSM). Both approvals are for patients with PDGFR-alpha genetic variants.

    April 26, 2022
    Oncology Drug Reference Sheet: Pafolacianine
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Pafolacianine

    An optical imaging agent shown to improve diagnostic accuracy, pafolacianine (CytaluxTM) was approved on November 29, 2021, for use in adult patients with known or suspected ovarian cancer as adjunct therapy in conjunction with planned intraoperative identification of malignant lesions. Pafolacianine is used in combination with a near-infrared (NIR) fluorescence imaging system that requires specialized training provided by the device manufacturer.

    March 22, 2022
    Oncology Drug Reference Sheet: Tisotumab Vedotin-Tftv
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Tisotumab Vedotin-Tftv

    In clinical trials, 24% of patients achieved an objective response rate with tisotumab vedotin-tftv (TivdakTM) that lasted a median of 8.3 months, leading to the agent’s U.S. Food and Drug Administration September 2021 approval for use in adults with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

    February 22, 2022
    Oncology Drug Reference Sheet: Ivosidenib
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Ivosidenib

    Adding to its earlier approvals for use in adults with acute myeloid leukemia (AML), on August 25, 2021, the U.S. Food and Drug Administration (FDA) approved ivosidenib (Tibsovo®) for adults with previously treated, locally advanced or metastatic cholangiocarcinoma. Cholangiocarcinoma, or cancer of the bile ducts, is a rare cancer, and ivosidenib is the only currently approved agent for patients with an IDH1 variant.

    January 25, 2022
    Oncology Drug Reference Sheet: Amivantamab-Vmjw
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Amivantamab-Vmjw

    After clinical trials demonstrated a 40% overall response rate with 63% of responses lasting six months or more, on May 21, 2021, the U.S. Food and Drug Administration (FDA) approved amivantamab-vmjw (RybrevantTM) for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion variants, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

    December 28, 2021
    Oncology Drug Reference Sheet: Sotorasib
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Sotorasib

    After clinical trials demonstrated an overall response rate of 36% and median response duration of 10 months, the U.S. Food and Drug Administration granted sotorasib (LumakrasTM) accelerated approval on May 28, 2021, for the treatment of adults with KRAS G12C–altered locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.

    November 23, 2021
    Oncology Drug Reference Sheet: Belantamab Mafodotin-Blmf
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Belantamab Mafodotin-Blmf

    A first-of-its-kind antibody-drug conjugate for multiple myeloma, belantamab mafodotin-blmf (Blenrep) received accelerated approval from the U.S. Food and Drug Administration (FDA) in August 2020. The approval was based on clinical trial findings that demonstrated a 31% overall response rate that lasted at least six months in 73% of responders.

    October 26, 2021
    Oncology Drug Reference Sheet: Sacituzumab Govitecan-Hziy
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Sacituzumab Govitecan-Hziy

    Initially marketed in April 2020 for treatment of adults with metastatic triple negative breast cancer, sacituzumab govitecan-hziy (Trodelvy®) received an additional approval in 2021 for the treatment of patients with locally advanced or metastatic urothelial cancer with prior treatments.

    September 28, 2021
    Oncology Drug Reference Sheet: Tivozanib
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Tivozanib

    On March 10, 2021, the U.S. Food and Drug Administration approved tivozanib (Fotivda®), an oral kinase inhibitor, for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.

    August 24, 2021
    FDA Approves Pembrolizumab for High-Risk, Early-Stage, Triple-Negative Breast Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Pembrolizumab for High-Risk, Early-Stage, Triple-Negative Breast Cancer

    On July 26, 2021, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda®) for high-risk, early-stage, triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment and continued as a single agent as adjuvant treatment after surgery. 

    July 27, 2021
    Oncology Drug Reference Sheet: Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf Subcutaneous Injection
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf Subcutaneous Injection

    Pertuzumab, trastuzumab, and hyaluronidase-zzxf subcutaneous injection (PhesgoTM) was approved by the U.S. Food and Drug Administration (FDA) in June 2020 for patients with advanced HER2-positive breast cancer. The drug components are the same as those in FDA-approved IV version, and study results showed comparable safety and efficacy to the IV counterparts. The new administration route allows eligible patients to bypass infusion centers or even receive the therapy at home.

    July 27, 2021
    FDA Grants Regular Approval to Enfortumab Vedotin-Ejfv for Locally Advanced or Metastatic Urothelial Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Grants Regular Approval to Enfortumab Vedotin-Ejfv for Locally Advanced or Metastatic Urothelial Cancer

    On July 9, 2021, the U.S. Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv ([EV], Padcev®), a Nectin-4–directed antibody and microtubule inhibitor conjugate, for adult patients with locally advanced or metastatic urothelial cancer who previously received a programmed death receptor-1 (PD-1) or programmed death-ligand (PD-L1) inhibitor and platinum-containing chemotherapy or are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.

    July 09, 2021
    Oncology Drug Reference Sheet: Tepotinib
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Tepotinib

    Tepotinib (Tepmetko®) was granted accelerated approval in February 2021 for mesenchymalepithelial transition (MET)-altered metastatic non-small cell lung cancer (NSCLC) based on overall response rate and duration. The drug is still under long-term evaluation and healthcare providers should report all serious adverse events that may be associated to FDA’s MedWatch Reporting System.

    June 22, 2021
    Oncology Drug Reference Sheet: Trilaciclib
    Clinical practice

    Oncology Drug Reference Sheet: Trilaciclib

    On February 12, 2021, the U.S. Food and Drug Administration approved trilaciclib (CoselaTM), a parenteral inhibitor of cyclin-dependent kinase, to prevent myelosuppression when administered prior to chemotherapy administration. The approval is currently limited to the use of trilaciclib before treatment with platinum- and etoposide-containing regimens and topotecan-containing regimens for treatment of extensive-stage small cell lung cancer.

    May 25, 2021
    Oncology Drug Reference Sheet: Relugolix
    Clinical practice

    Oncology Drug Reference Sheet: Relugolix

    On December 18, 2020, the U.S. Food and Drug Administration approved relugolix (OrgovyxTM) as the first oral hormone therapy for use in adult patients with advanced prostate cancer. 

    April 27, 2021
    Oncology Drug Reference Sheet: Decitabine and Cedazuridine
    Cancer treatments

    Oncology Drug Reference Sheet: Decitabine and Cedazuridine

    In July 2020, the U.S. Food and Drug Administration approved decitabine and cedazuridine (Inqovi®) tablets for the treatment of adults with myelodysplastic syndromes. 

    March 30, 2021
    Oncology Drug Reference Sheet: Tafasitamab-Cxix
    Oncology drug research

    Oncology Drug Reference Sheet: Tafasitamab-Cxix

    Tafasitamab-cxix (Monjuvi®) received accelerated approval from the U.S. Food and Drug Administration in July 2020 in combination with lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma.

    January 26, 2021
    Oncology Drug Reference Sheet: Alpelisib
    Clinical practice

    Oncology Drug Reference Sheet: Alpelisib

    When used in combination with fulvestrant, alpelisib (Piqray®) produced complete or partial responses in 29% of patients with PIK3CA-altered, estrogen receptor-positive advanced breast cancer in clinical trials. The U.S. Food and Drug Administration approved it for use in 2019.

    December 29, 2020
    Oncology Drug Reference Sheet: Selpercatinib
    Clinical practice

    Oncology Drug Reference Sheet: Selpercatinib

    In May 2020, the U.S. Food and Drug Administration gave accelerated approval for selpercatinib (Retevmo®) to treat RET-altered non-small cell lung cancer or thyroid cancer based on overall response rate and duration of response. Selpercatinib fights cancer by impeding RET protein activity. The determining clinical trial results demonstrated that it reduced tumor size in more than 50% of patients and was associated with fewer adverse reactions than other drugs that block the RET protein.

    November 24, 2020
    Oncology Drug Reference Sheet: Lurbinectedin
    Clinical practice

    Oncology Drug Reference Sheet: Lurbinectedin

    In June 2020, the U.S. Food and Drug Administration granted accelerated approval to lurbinectedin (ZepzelcaTM) for adults with metastatic small cell lung cancer (SCLC) whose disease has progressed on or after platinum-based chemotherapy. The approval adds a second choice for patients who experience treatment-resistant SCLC progression, who previously had only topotecan as an option.

    October 20, 2020
    Oncology Drug Reference Sheet: Zanubrutinib
    Clinical practice

    Oncology Drug Reference Sheet: Zanubrutinib

    Zanubrutinib (BrukinsaTM) received U.S. Food and Drug Administration accelerated approval on November 14, 2019, for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.

    September 22, 2020
    Oncology Drug Reference Sheet: Rucaparib
    Clinical practice

    Oncology Drug Reference Sheet: Rucaparib

    Rucaparib (Rubraca®) has U.S. Food and Drug Administration approval for both maintenance and treatment indications in gynecologic cancers. It originally received accelerated approval in 2016 for the treatment of deleterious, BRCA variant–associated advanced ovarian cancer that has failed two or more chemotherapies. In 2018, it was approved for maintenance therapy of various gynecologic malignancies. Most recently, rucaparib received approval for BRCA-positive metastatic castration-resistant prostate cancer treatment after androgen-directed and chemotherapy.

    August 25, 2020
    Oncology Drug Reference Sheet: Enfortumab Vedotin-Ejfv
    U.S. Food and Drug Administration (FDA)

    Oncology Drug Reference Sheet: Enfortumab Vedotin-Ejfv

    Enfortumab vedotin-ejfv (Padcev™) was granted accelerated approval in December 2019 for adults with locally advanced or metastatic urothelial cancer who previously received an immune checkpoint inhibitor (PD-1 or PD-L1 inhibitor) and platinum-containing therapy.

    July 28, 2020
    Oncology Drug Reference Sheet: Capecitabine
    Prescription medication

    Oncology Drug Reference Sheet: Capecitabine

    Capecitabine (Xeloda®) was approved by the U.S. Food and Drug Administration (FDA) in 1998 as a nucleoside metabolic inhibitor with antineoplastic activity indicated for adjuvant colon cancer, metastatic colorectal cancer, and metastatic breast cancer.

    May 26, 2020
    Oncology Drug Reference Sheet: Daratumumab
    Oncology drug research

    Oncology Drug Reference Sheet: Daratumumab

    Daratumumab (Darzalex®) was originally approved by the U.S. Food and Drug Administration in 2015 with additional indications added since. The most recent new indication was approved in September 2019 for newly diagnosed patients with multiple myeloma who are eligible for autologous stem cell transplantation. In May 2020, daratumumab and hyaluronidase-fihj (Darzalex Faspro™), a subcutaneous (SQ) formulation, was approved.

    April 28, 2020
    Oncology Drug Reference Sheet: Tocilizumab (Actemra®)
    COVID-19

    Oncology Drug Reference Sheet: Tocilizumab

    Tocilizumab was approved in August 2017 for the treatment of chimeric antigen receptor T cell–induced cytokine release syndrome. In March 2020, the U.S. Food and Drug Administration approved a randomized, double-blind, placebo-controlled, phase III clinical trial to assess the safety and efficacy of tocilizumab plus standard of care in patients hospitalized with severe COVID-19 pneumonia.

    April 14, 2020
    Oncology Drug Reference Sheet: Panitumumab (Vectibix®)
    Prescription medication

    Oncology Drug Reference Sheet: Panitumumab

    Approved in 2006 as monotherapy for the treatment of patients with EGFR-expressing metastatic colorectal cancer (mCRC) after disease progression following treatment, panitumumab has been a mainstay metastatic disease for more than a decade. In 2014, it received additional indication as first-line therapy for the treatment of patients with EGFR-expressing mCRC in combination with FOLFOX, but in 2017, use was narrowed to wild-type RAS (not mutated RAS). 

    March 23, 2020
    Oncology Drug Reference Sheet: Niraparib
    Treatments

    Oncology Drug Reference Sheet: Niraparib

    Niraparib was approved in October 2019 for patients with homologous recombination deficiency (HRD)-positive advanced ovarian, fallopian tube, or primary peritoneal cancer. 

    February 25, 2020
    Oncology Drug Reference Sheet: Entrectinib
    Treatments

    Oncology Drug Reference Sheet: Entrectinib

    Entrectinib was approved by the U.S. Food and Drug Administration in August 2019 as the third tumor-agnostic cancer drug, meaning it targets a specific mutation of the cancer, not the organ of origin. The other two currently approved tumor-agnostic drugs are larotrectinib and pembrolizumab.

    January 21, 2020
    Oncology Drug Reference Sheet: Radium 223 Dichloride
    Treatments

    Oncology Drug Reference Sheet: Radium 223 Dichloride

    Radium 223 dichloride (Xofigo®) is an alpha particle-emitting radioactive therapeutic agent approved by the U.S. Food and Drug Administration in 2013 for castrate-resistant prostate cancer.

    December 24, 2019
    • Current page 1
    • Page 2
    • Next page
    • Last page Last »
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    • ONS Congress Newscast
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    View All Topics
     
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2023 Oncology Nursing Society
     
    Back to Top ▲